Ranbaxy CFO quits 6 months after CEO exit

More turmoil for India's Ranbaxy Laboratories. CFO Omesh Sethi has left the company, becoming the third top executive to do so since its Japanese majority owner took control. Moreover, Sethi is leaving only six months after CEO Atul Sobti took a hike, saying his vision for the company didn't mesh with Daiichi's.

Daiichi confirmed Sethi's departure to Bloomberg, but wouldn't comment beyond that. Ranbaxy didn't offer a reason for the change, just saying it was effective Tuesday.

It's rarely a good time to lose two top managers in quick succession. As CLSA Asia-Pacific Markets analyst Hemant Bakru told Bloomberg, "You lose that continuity which is essential for any corporation to run well." But needless to say, it's an especially bad time for Ranbaxy. Two years into an import ban, the company is still trying to mend its relationship with FDA. Constrained in the important U.S. market, Ranbaxy's sales have suffered; for 2009, its most recent full-year results, sales grew by only 2.5 percent.

- read the Reuters story
- check out the coverage from Bloomberg

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.